Alnylam (ALNY) Targets 25% CAGR with Innovative Therapies

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) ranks among the best rebound stocks to buy right now. On March 2, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) outlined its growth strategy at the TD Cowen 46th Annual Health Care Conference, emphasizing significant revenue expansion and ongoing innovation in RNAi therapies. The company expects revenue of around $4.4 billion to $4.7 billion by 2026, indicating strong growth and a 25% CAGR through 2030. It also aims for 30% operating margins, which might rise to ...